- Cancer Innovations Newsletter
- Posts
- AI tool predicts 80% of ovarian cancer therapy outcomes
AI tool predicts 80% of ovarian cancer therapy outcomes
PLUS: Unfold AI receives FDA clearance
Howdy
Here is the latest issue of the Cancer Innovations newsletter.
If you have any questions, feel free to hit reply. You can also find me on Twitter @thomassorheim
- Thomas
Today’s topics
Unfold AI in Prostate Cancer Receives FDA Clearance
AI-powered method for cancer treatment by interpreting tumor tissue data
AI tool predicts 80% of ovarian cancer therapy outcomes
Unfold AI in Prostate Cancer Receives FDA Clearance
A Stanford study has shown the efficacy of Avenda Health's Unfold AI in prostate cancer treatment, surpassing traditional methods by encapsulating 80% of clinically significant cancer. The AI integrates biopsy and imaging data for improved cancer risk and margin assessment.
This year, unfold AI was awarded a category III CPT code and FDA clearance.
According to Unfold AI, most prostate cancers are invisible on MRI. When removing the cancer by surgery, the doctors must balance sparing healthy tissue and preserve quality of life while minimizing the risk of leaving cancer behind. Unfold AI marks a significant advance in personalized prostate cancer care.
News coverage:
Doctors:
Company & AI:
Institutions mentioned:
AI-powered method for cancer treatment by interpreting tumor tissue data
Researchers at Karolinska Institutet and SciLifeLab in Sweden have developed a groundbreaking AI-powered method for cancer treatment by interpreting tumor tissue data. Drawing inspiration from analysis techniques in satellite imaging and community ecology, dating back to the 1950s and 2000s, they have created a system that can handle the vast data generated by modern tumor imaging. This approach overcomes the limitations of traditional AI methods, which often act as a "black box," providing results without clear explanations. These new advances with AI can lead to more tailor-made and personalized treatments for each individual's needs and potentially reduce side effects.
Link to research paper: Nature Communications
News coverage: News Medical
Doctor’s mentioned:
Anissa EL MARRAHI
Institutions mentioned:
AI tool predicts 80% of ovarian cancer therapy outcomes
In a study with 134 patients published, the AI tool IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy) marks a significant advance in personalized oncology. Developed by Prof. Evis Sala's team, IRON achieves an 80% accuracy in predicting ovarian cancer therapy outcomes, doubling the current standard. The AI analyzes patient-specific data, including tumor DNA and CT scans, to tailor treatment plans. IRON's success in the study heralds a new era in precise, personalized ovarian cancer care.
Link to research paper: Nature Communications
News coverage: SciTechDaily
Doctor’s mentioned:
Ramona Woitek
Marika A. V. Reinius
Elizabeth Moore
Lucian Beer
Vlad Bura
Leonardo Rundo
Cathal McCague
Stephan Ursprung
Lorena Escudero Sanchez
Paula Martin-Gonzalez
Florent Mouliere
Dineika Chandrananda
James Morris
Teodora Goranova
Anna M. Piskorz
Naveena Singh
Anju Sahdev
Roxana Pintican
Marta Zerunian
Nitzan Rosenfeld
Helen Addley
Mercedes Jimenez-Linan
Florian Markowetz
James D. Brenton
Institutions mentioned: